Viewing Study NCT05266404


Ignite Creation Date: 2025-12-24 @ 9:14 PM
Ignite Modification Date: 2025-12-29 @ 4:57 AM
Study NCT ID: NCT05266404
Status: COMPLETED
Last Update Posted: 2022-07-05
First Post: 2022-02-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module